Cargando…

Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents

During the past decade, intravenous iron supplementation to ESA (erythropoiesis-stimulating agent) therapy has emerged as an option to augment hemoglobin response in anemic cancer patients. In this paper, the results of seven published randomized clinical trials assessing the role of iron supplement...

Descripción completa

Detalles Bibliográficos
Autor principal: Karlsson, Torbjörn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scholarly Research Network 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196863/
https://www.ncbi.nlm.nih.gov/pubmed/22111015
http://dx.doi.org/10.5402/2011/108397
_version_ 1782214243619176448
author Karlsson, Torbjörn
author_facet Karlsson, Torbjörn
author_sort Karlsson, Torbjörn
collection PubMed
description During the past decade, intravenous iron supplementation to ESA (erythropoiesis-stimulating agent) therapy has emerged as an option to augment hemoglobin response in anemic cancer patients. In this paper, the results of seven published randomized clinical trials assessing the role of iron supplementation to ESA therapy in the hematology/oncology setting will be discussed. The pathogenetic mechanisms behind functional iron deficiency, a major reason for ESA hyporesponsiveness in cancer, will also be described.
format Online
Article
Text
id pubmed-3196863
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher International Scholarly Research Network
record_format MEDLINE/PubMed
spelling pubmed-31968632011-11-22 Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents Karlsson, Torbjörn ISRN Hematol Review Article During the past decade, intravenous iron supplementation to ESA (erythropoiesis-stimulating agent) therapy has emerged as an option to augment hemoglobin response in anemic cancer patients. In this paper, the results of seven published randomized clinical trials assessing the role of iron supplementation to ESA therapy in the hematology/oncology setting will be discussed. The pathogenetic mechanisms behind functional iron deficiency, a major reason for ESA hyporesponsiveness in cancer, will also be described. International Scholarly Research Network 2011 2011-10-13 /pmc/articles/PMC3196863/ /pubmed/22111015 http://dx.doi.org/10.5402/2011/108397 Text en Copyright © 2011 Torbjörn Karlsson. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Karlsson, Torbjörn
Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents
title Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents
title_full Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents
title_fullStr Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents
title_full_unstemmed Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents
title_short Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents
title_sort effects of iron supplementation on erythropoietic response in patients with cancer-associated anemia treated by means of erythropoietic stimulating agents
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196863/
https://www.ncbi.nlm.nih.gov/pubmed/22111015
http://dx.doi.org/10.5402/2011/108397
work_keys_str_mv AT karlssontorbjorn effectsofironsupplementationonerythropoieticresponseinpatientswithcancerassociatedanemiatreatedbymeansoferythropoieticstimulatingagents